EUVIMEDEUVIMED entdecken
Open Access

Influenza Vaccine Effectiveness Against Influenza A–Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022–2023

Mark W Tenforde iD, Zachary A Weber, Duck-Hye Yang, Malini B DeSilva iD, Kristin Dascomb, Stephanie A Irving, Allison L Naleway, Manjusha Gaglani iD, Bruce Fireman, Ned Lewis, Ousseny Zerbo iD, Kristin Goddard und 23 weitere

The Journal of Infectious Diseases · 25.07.2024 · 230 (1) · 141-151

DOI: 10.1093/infdis/jiad542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 02.12.2023. Verfasst von Mark W Tenforde und 34 weiteren Autor:innen. Beteiligte Einrichtung: Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia. Hauptthemen laut MEDLINE: Influenza, Human, Influenza Vaccines, Hospitalization, Emergency Service, Hospital. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS, CDC HHS, Centers for Disease Control and Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The 2022–2023 United States influenza season had unusually early influenza activity with high hospitalization rates. Vaccine-matched A(H3N2) viruses predominated, with lower levels of A(H1N1)pdm09 activity also observed.

Methods

Using the test-negative design, we evaluated influenza vaccine effectiveness (VE) during the 2022–2023 season against influenza A–associated emergency department/urgent care (ED/UC) visits and hospitalizations from October 2022 to March 2023 among adults (aged ≥18 years) with acute respiratory illness (ARI). VE was estimated by comparing odds of seasonal influenza vaccination among case-patients (influenza A test positive by molecular assay) and controls (influenza test negative), applying inverse-propensity-to-be-vaccinated weights.

Results

The analysis included 85 389 ED/UC ARI encounters (17.0% influenza A positive; 37.8% vaccinated overall) and 19 751 hospitalizations (9.5% influenza A positive; 52.8% vaccinated overall). VE against influenza A–associated ED/UC encounters was 44% (95% confidence interval [CI], 40%–47%) overall and 45% and 41% among adults aged 18–64 and ≥65 years, respectively. VE against influenza A–associated hospitalizations was 35% (95% CI, 27%–43%) overall and 23% and 41% among adults aged 18–64 and ≥65 years, respectively.

Conclusions

VE was moderate during the 2022–2023 influenza season, a season characterized with increased burden of influenza and co-circulation with other respiratory viruses. Vaccination is likely to substantially reduce morbidity, mortality, and strain on healthcare resources.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza, HumanInfluenza VaccinesHospitalizationEmergency Service, HospitalVaccine EfficacyHumansMiddle AgedAdultMaleFemaleUnited StatesAgedYoung AdultAdolescentInfluenza A Virus, H3N2 SubtypeInfluenza A Virus, H1N1 SubtypeAmbulatory CareVaccinationSeasons

Stichwörter der Autor:innen

H3N2clinical outcomesinfluenzatest-negative designvaccine effectiveness

Substanzen

Influenza Vaccines

Autor:innen und Institutionen

  • Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Department of Clinical Resarch, Westat, Rockville, Maryland.
  • Department of Research, HealthPartners Institute, Minneapolis, Minnesota.
  • Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah.
  • Department of Science Programs, Kaiser Permanente Center for Health Research, Portland, Oregon.
  • Section of Pediatric Infectious Diseases, Department of Pediatrics, Baylor Scott & White Health and Baylor College of Medicine, Temple, Texas.

ORCID-Profile: Mark W Tenforde, Malini B DeSilva, Manjusha Gaglani, Ousseny Zerbo, John R Hansen, Suchitra Rao, Shaun J Grannis, Karthik Natarajan, Palak Patel, Katherine Adams

Förderung

  • Intramural CDC HHS
  • CDC HHS
  • Centers for Disease Control and Prevention

Zitieren

APA

Tenforde, M. W., Weber, Z. A., Yang, D. H., DeSilva, M. B., Dascomb, K., Irving, S. A., Naleway, A. L., Gaglani, M., Fireman, B., Lewis, N., Zerbo, O., Goddard, K., Timbol, J., Hansen, J. R., Grisel, N., Arndorfer, J., McEvoy, C. E., Essien, I. J., Rao, S., …, & Klein, N. P. (2024). Influenza Vaccine Effectiveness Against Influenza A–Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022–2023. The Journal of Infectious Diseases, 230(1), 141-151. https://doi.org/10.1093/infdis/jiad542

Vancouver

Tenforde MW, Weber ZA, Yang DH, DeSilva MB, Dascomb K, Irving SA, et al. Influenza Vaccine Effectiveness Against Influenza A–Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022–2023. The Journal of Infectious Diseases. 2024;230(1):141-151. doi:10.1093/infdis/jiad542

BibTeX
@article{Tenforde2024,
  author = {Tenforde, Mark W and Weber, Zachary A and Yang, Duck-Hye and DeSilva, Malini B and Dascomb, Kristin and Irving, Stephanie A and Naleway, Allison L and Gaglani, Manjusha and Fireman, Bruce and Lewis, Ned and Zerbo, Ousseny and Goddard, Kristin and Timbol, Julius and Hansen, John R and Grisel, Nancy and Arndorfer, Julie and McEvoy, Charlene E and Essien, Inih J and Rao, Suchitra and Grannis, Shaun J and Kharbanda, Anupam B and Natarajan, Karthik and Ong, Toan C and Embi, Peter J and Ball, Sarah W and Dunne, Margaret M and Kirshner, Lindsey and Wiegand, Ryan E and Dickerson, Monica and Patel, Palak and Ray, Caitlin and Flannery, Brendan and Garg, Shikha and Adams, Katherine and Klein, Nicola P},
  title = {Influenza Vaccine Effectiveness Against Influenza A–Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022–2023},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  volume = {230},
  number = {1},
  pages = {141--151},
  doi = {10.1093/infdis/jiad542}
}
Kostenlos starten →